ArticleBMC infectious diseases2026
In the shadow of COVID-19: changes in the seroprevalence of pediatric Mycoplasma pneumoniae.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMycoplasma pneumoniae (MP) is a leading cause of respiratory tract infections in children. The coronavirus disease 2019 (COVID-19) pandemic has significantly heightened global attention to respiratory infections, including MP. This retrospective study analyzed the MP seroprevalence among children with acute respiratory tract infections (ARTIs) in Nantong, China, across different phases of the COVID-19 pandemic to assess the changes in the epidemiological landscape of MP in children.
methodsThis study retrospectively analyzed MP-IgM antibody test data from 56,411 children aged 0–14 years with ARTIs at the Affiliated Maternity and Child Health Care Hospital of Nantong University between April 2018 and September 2024. The study period was divided into three phases: pre-pandemic (April 2018–January 2020), pandemic (January 2020–January 2023), and post-pandemic (January 2023–September 2024). Chemiluminescent immunoassay (CLIA) was used to detect serum MP-IgM antibodies, and comparisons were made across the three phases regarding the sex distribution, age distribution, positivity rates, antibody titers, and temporal distribution patterns.
resultsThe overall MP-IgM positivity rate was 33.39% (18,833/56,411). Positivity rates exhibited a “V”-shaped fluctuation across the three phases, with rates of 39.70% (6,038/15,209) pre-pandemic, 30.12% (6,553/21,758) during the pandemic, and 32.10% (6,242/19,444) post-pandemic (χ²=391.564, P < 0.001). Significant differences in positivity rate distribution occurred among age groups, with the highest positivity rates in the 3 ~ < 6 years group. In the post-pandemic phase, there was a marked increase in infection rates in the ≥ 6 years group (P < 0.001). There were significant differences in the monthly MP positivity rates every year but 2022 (P < 0.05). Significant fluctuations in MP-IgM antibody titers were observed across phases, with the median titer decreasing from 1.80 (IQR: 1.22–3.18) COI pre-pandemic to 1.65(IQR: 1.18–2.67) COI during the pandemic, and subsequently rebounding to 2.16(IQR: 1.31–4.30) COI post-pandemic (H = 368.022, P < 0.001).
conclusionThe epidemiological pattern of MP was significantly altered by the COVID-19 pandemic. The rebound in MP infection rates and the marked increase in antibody titers post-pandemic suggest the need to adjust control strategies for pediatric respiratory infections to address shifts in the patterns of MP epidemics. Moreover, the dynamic changes in MP-IgM titers provide novel insights into the evolution of immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.